Onconano Medicine Raises ~$50 Million In Series B Financing
PRIVATEJun 17, 2021
Amount Raised
$50 Million
Round Type
Series B
DallasBiotechnologyHealth CareMedicalTherapeutics
Description
OncoNano Medicine, Inc. today announced the raise of an approximate $50 million Series B financing led by the healthcare investment team at Advantech Capital, a China-based cross border institutional investment fund. Proceeds of the financing will be used, in part, to support the Phase 3 clinical trials in the U.S. and Europe for pegsitacianine, an innovative real-time imaging agent used in intraoperative surgical resection of solid tumors, and accelerate the advancement of the company’s first therapeutic development program, ONM-501, a novel immune-therapeutic formulated with the company’s core delivery technology.
Company Information
Company
OncoNano Medicine
Location
3060 Pegasus Park Drive
Dallas, Texas, United States
About
OncoNano is harnessing the power of nanotechnology to unlock a new era of targeted therapeutics. Our ON-BOARD™ polymeric micelle platform exploits the highly acidic tumor microenvironment, a byproduct of cancer metabolism, to precisely deliver therapeutic payloads directly to the tumor site. OncoNano’s product candidates are designed to improve the pharmacokinetic and pharmacodynamic properties of various payloads from small molecules to large biologics through encapsulation and localized tumor targeting.
Fundz sees it the moment OncoNano Medicine raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
DallasBiotechnologyHealth CareMedicalTherapeutics